Effects of meningitis C jab may wear off

June 6, 2008 Effects of meningitis C jab may wear off

A booster dose of vaccine after the age of 10 may be needed.

One in five 11–13 year olds appear to have low antibodies against meningitis C after being immunised as young children, suggests an Oxford University study published in the British Medical Journal.

In 1999–2000 the government ran a meningitis C immunisation campaign that vaccinated everyone between the ages of 1 and 18 years old and the number of cases dropped dramatically. Ever since, the vaccine has been part of the routine infant immunisation programme. Last year, for the first time, no one died of meningitis C disease.

However studies have shown that the vaccine’s effectiveness in infants drops over time as the level of protective antibodies in their bodies falls.

As teenagers used to be considered a group at high risk of contracting meningitis C, the researchers set out to determine whether those who had been immunised in 1999–2000 are still sufficiently protected against the disease as they reach adolescence.

Dr Matthew Snape and colleagues at the Oxford Vaccine Group took blood samples from 999 adolescents to see if they had antibody levels sufficiently high to provide protection against the disease.

The majority of all the 11–20 year olds had sufficient levels of antibodies to remain protected. However, approximately 90 per cent of the 14–20 age group had that level of protection compared to 80% of the 11–13 age group.

This means that over the coming years, a group of children will be entering adolescence in which over 20 per cent – ‘a significant minority’ – do not have sufficient levels of antibodies to protect them.

The researchers found that children who were aged 10 or over when vaccinated maintained protective levels of antibodies for longer, and suggest that one possible cause is maturation of the immune system at around the age of 10.

A booster dose of vaccine after the age of 10 may be needed to sustain protection against meningitis C amongst teenagers, say the researchers.

Source: Oxford University


print this article email this article download pdf blog this article bookmark this article     Stumble it Digg this share on Facebook retweet share on Reddit add to delicious
Rate this story - not rated yet


June 6, 2008 all stories

Comments: 0

not rated yet
  • Stumble this up

  • Digg this

  • share this

  • hide
  • Related Stories




  • hide
  • Relevant PhysicsForums posts

Other News

A child sleeping (Sleep)

Dreams may have an important physiological function

Medicine & Health / Neuroscience

created Nov 12, 2009 | popularity 3.9 / 5 (25) | comments 10

(PhysOrg.com) -- Dreams have long been assumed to have psychological functions such as consolidating emotional memories and processing experiences or problems, but according to a Harvard psychiatrist and sleep ...


China investigates 2 deaths after flu vaccinations

Medicine & Health / Diseases

created 20 hours ago | popularity not rated yet | comments 0

(AP) -- Two people in China who received swine flu vaccinations died in the past week but at least one death appears unrelated to the vaccine and the other was being investigated.


FDA questions safety of alcoholic energy drinks

Medicine & Health / Health

created Nov 13, 2009 | popularity 3.7 / 5 (3) | comments 7

(AP) -- The Food and Drug Administration is challenging makers of alcohol-infused energy drinks to prove their beverages are safe, citing complaints that the products can cause risky behavior and injury.


Deepening the search  for clues to rheumatoid arthritis

Deepening the search for clues to rheumatoid arthritis

Medicine & Health / Genetics

created Nov 09, 2009 | popularity 5 / 5 (3) | comments 10

(PhysOrg.com) -- The gnawing pain of rheumatoid arthritis is a signal that the body’s immune system has hit the wrong target: its own cartilage and bone.


Review: Reports on Pfizer drug studies misleading

Medicine & Health / Medications

created Nov 11, 2009 | popularity 3.8 / 5 (4) | comments 5

(AP) -- Analysis of a dozen published studies testing possible new uses for a Pfizer Inc. epilepsy drug found that reporting of the results was often fudged, indicating the medicine worked better than internal company documents ...